Tectonic Therapeutic (TECX) CEO receives option and RSU equity grants

Rhea-AI Filing Summary

REICIN ALISE reported acquisition or exercise transactions in this Form 4 filing.

Tectonic Therapeutic, Inc. director and Chief Executive Officer Alise Reicin reported equity awards and updated holdings. On March 4, 2026, she was granted an employee stock option for 69,250 shares and a grant of 76,500 shares of common stock represented by restricted stock units.

The restricted stock units vest in three equal annual installments on March 4, 2027, March 4, 2028 and March 4, 2029, subject to her continued service. The option vests in 48 equal monthly installments beginning on April 4, 2026, also subject to continued service.

The filing also notes 127,030 shares of common stock held indirectly through the Reicin-Boiarsky Family Trust, where her spouse is a co-trustee and she may share voting and dispositive power, while disclaiming beneficial ownership beyond any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REICIN ALISE

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		76,500(1)	A	$0	311,547	D
Common Stock								127,030	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$27.41	03/04/2026		A		69,250		(3)	03/03/2036	Common Stock	69,250	$0	69,250	D

Explanation of Responses:

1. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TECX CEO Alise Reicin report on March 4, 2026?

Alise Reicin reported equity awards rather than open-market trades. She received an option for 69,250 shares and 76,500 shares of common stock via restricted stock units, plus updated disclosure of indirect holdings through a family trust associated with her and her spouse.

How do the TECX restricted stock units granted to the CEO vest?

The restricted stock units granted to the TECX CEO vest over three years. They vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, and each vesting date requires her continued service with Tectonic Therapeutic.

What is the vesting schedule for the TECX stock options granted to the CEO?

The stock options granted to the TECX CEO vest monthly over four years. The award covers 69,250 shares and vests in 48 equal monthly installments starting April 4, 2026, contingent on her continued service to Tectonic Therapeutic on each vesting date.

What indirect TECX share holdings are reported through the Reicin-Boiarsky Family Trust?

The Form 4 reports 127,030 TECX common shares held indirectly by the Reicin-Boiarsky Family Trust. The CEO’s spouse is a co-trustee, and she may share voting and dispositive power, while disclaiming beneficial ownership beyond any pecuniary interest in the trust’s securities.

Does the TECX Form 4 show the CEO buying or selling shares on the market?

The TECX Form 4 reflects equity grants and holdings, not open-market trades. It records stock option and restricted stock unit awards to the CEO and indirect trust holdings, with no reported market purchases or sales of Tectonic Therapeutic common stock in this filing.